Supplementary Tables S1-S11 for: Neutralization over Conformation: Redefining Antibody Screening Strategy for In Vitro Potency Test of Rabies Vaccines

本数据集包含用于支持题为《Neutralization over Conformation: Redefining Antibody Screening Strategy for In Vitro Potency Test of Rabies Vaccines》的研究论文的全部补充表格（S1-S11）。本研究旨在优化狂犬病疫苗体外效力评估的抗体筛选策略，验证了中和活性导向的抗体配对方案相较于传统构象结合导向策略的优越性。本数据集为此提供了完整的实验数据支撑。数据集具体内容包括：表S1：四种单克隆抗体（S037， S053， S010， S036）的RFFIT（快速荧光灶抑制试验）中和效价（IU/mg）测定结果，包含三次独立重复实验及平均值。表S2：上述抗体在13个连续稀释梯度（1:400 至 1:831,200）下的酶联免疫吸附试验（ELISA）光密度（OD450nm）测量值（双重复）。表S3-S4：抗体在EDC-NHS化学偶联处理前后的Zeta电位变化详细数据。表S5：表征抗体-抗原相互作用的实时动力学结合曲线数据（基线校正后的mAu vs. Time）。表S6与S7：基于四种不同抗体组合（S037+S053， S036+S010， S037+S036， S010+S053）的狂犬病病毒糖蛋白（GP）体外效力测定的相对发光单位（RLU）值，及其与GP标准品效价（mIU/mL）的线性回归分析结果（含R²， P值及拟合方程）。表S8-S10：针对四种不同狂犬病毒固定毒株（PV， PM， AG， CTN），将新建的化学发光免疫分析法（CLIA）与经典的小鼠NIH效力测试法进行对比的详尽效价（IU/mL）数据、两组数据的差值-均值分析及回归统计结果。表S11：从78份疫苗样品中选取的代表性样本，其CLIA法与NIH法效力测定结果的并列对比汇总。这些数据从抗体特性、方法学建立到临床前样本验证三个层面，完整证明了基于中和活性的抗体配对策略能够建立与体内效力标准（NIH法）高度相关的体外效价检测方法。本数据集为文中所有图表和统计分析提供了原始与衍生数据，旨在确保研究的可重复性、可验证性和透明度。访问说明：为保护同行评审过程的机密性，在相关论文正式发表前，本数据集设置为受限访问。审稿人与编辑可通过平台申请快速获取。

This dataset contains all supplementary tables (S1–S11) supporting the research paper titled *Neutralization over Conformation: Redefining Antibody Screening Strategy for In Vitro Potency Test of Rabies Vaccines*. This study aims to optimize the antibody screening strategy for in vitro potency assessment of rabies vaccines, and validates the superiority of neutralization activity-directed antibody pairing schemes over traditional conformation-binding-directed strategies. This dataset provides complete experimental data support for this work.

Specific contents of the dataset are listed as follows:
Table S1: Determination results of rapid fluorescent focus inhibition test (RFFIT) neutralization titers (IU/mg) of four monoclonal antibodies (S037, S053, S010, S036), including three independent replicate experiments and their mean values.
Table S2: Enzyme-linked immunosorbent assay (ELISA) optical density (OD450nm) measurements (duplicate readings) of the aforementioned antibodies at 13 serial dilution gradients (1:400 to 1:831,200).
Tables S3–S4: Detailed data on Zeta potential changes of antibodies before and after EDC-NHS chemical coupling treatment.
Table S5: Real-time kinetic binding curve data characterizing antibody-antigen interactions (baseline-corrected mAu versus Time).
Tables S6 and S7: Relative light unit (RLU) values from in vitro potency assays of rabies virus glycoprotein (GP) based on four different antibody combinations (S037+S053, S036+S010, S037+S036, S010+S053), as well as linear regression analysis results between these values and GP standard titer (mIU/mL), including R², P-value and fitting equation.
Tables S8–S10: Comprehensive titer (IU/mL) data comparing the newly established chemiluminescent immunoassay (CLIA) with the classic mouse NIH potency test against four fixed rabies virus strains (PV, PM, AG, CTN), as well as difference-mean analysis and regression statistical results of the two datasets.
Table S11: Summary of side-by-side comparison of potency test results from CLIA and NIH methods for representative samples selected from 78 vaccine samples.

These data, covering three dimensions including antibody characterization, methodology establishment and preclinical sample validation, fully demonstrate that the neutralization activity-directed antibody pairing strategy can establish an in vitro potency detection method highly correlated with the in vivo potency standard (NIH method). This dataset provides original and derived data for all figures and statistical analyses in the paper, aiming to ensure the reproducibility, verifiability and transparency of the research.

Access Notice: To protect the confidentiality of the peer review process, this dataset is set to restricted access prior to the official publication of the corresponding paper. Reviewers and editors may apply for expedited access via the platform.